Evidence map›Paper›PMID 37321353›Full record

ArticleThe Journal of infection2023

Intradermal skin test with mRNA vaccines as a surrogate marker of T cell immunity in immunocompromised patients.

Benedict Fallet, Mathilde Foglierini, Raphael Porret, Ana Alcaraz-Serna, Christophe Sauvage, Raphael Jenelten, Teofila Caplanusi, Michel Gilliet, Laurent Perez, Craig Fenwick and 6 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of infection, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.6field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 3 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors at 3 institutions in 1 country.

Benedict FalletDivision of Immunology and Allergy, University Hospital of Lausanne, Switzerland.
Mathilde FoglieriniDivision of Immunology and Allergy, University Hospital of Lausanne, Switzerland; Biomedical Data Science Center, University Hospital of Lausanne, Switzerland.
Raphael PorretDivision of Immunology and Allergy, University Hospital of Lausanne, Switzerland.
Ana Alcaraz-SernaDivision of Immunology and Allergy, University Hospital of Lausanne, Switzerland.
Christophe SauvageCenter for Cell Immunotherapy, Department of Oncology and Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne, Lausanne CH-1066, Switzerland.
Raphael JeneltenDepartment of Dermatology and Venereology, University Hospital of Lausanne, Switzerland.
Teofila CaplanusiDepartment of Dermatology and Venereology, University Hospital of Lausanne, Switzerland.
Michel GillietDepartment of Dermatology and Venereology, University Hospital of Lausanne, Switzerland; University of Lausanne, Faculty of Biology and Medicine, Lausanne, Switzerland.
Laurent PerezDivision of Immunology and Allergy, University Hospital of Lausanne, Switzerland; University of Lausanne, Faculty of Biology and Medicine, Lausanne, Switzerland.
Craig FenwickDivision of Immunology and Allergy, University Hospital of Lausanne, Switzerland.
Raphael GenoletCenter for Cell Immunotherapy, Department of Oncology and Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne, Lausanne CH-1066, Switzerland.
Alexandre HarariCenter for Cell Immunotherapy, Department of Oncology and Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne, Lausanne CH-1066, Switzerland; University of Lausanne, Faculty of Biology and Medicine, Lausanne, Switzerland.
Sara BobisseCenter for Cell Immunotherapy, Department of Oncology and Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne, Lausanne CH-1066, Switzerland.
Raphael GottardoBiomedical Data Science Center, University Hospital of Lausanne, Switzerland; University of Lausanne, Faculty of Biology and Medicine, Lausanne, Switzerland; Swiss Institute for Bioinformatics, Lausanne, Switzerland.
Giuseppe PantaleoDivision of Immunology and Allergy, University Hospital of Lausanne, Switzerland; University of Lausanne, Faculty of Biology and Medicine, Lausanne, Switzerland.
Yannick D MullerDivision of Immunology and Allergy, University Hospital of Lausanne, Switzerland; University of Lausanne, Faculty of Biology and Medicine, Lausanne, Switzerland. Electronic address: Yannick.muller@chuv.ch.
University Hospital of Lausanne · CHLudwig Cancer Research · CHSIB Swiss Institute of Bioinformatics · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesIntradermal skin test (IDT) with mRNA vaccines may represent a simple, reliable, and affordable tool to measure T cell response in immunocompromised patients who failed to mount serological responses following vaccination with mRNA covid-19 vaccines.

methodsWe compared anti-SARS-CoV-2 antibodies and cellular responses in vaccinated immunocompromised patients (n = 58), healthy seronegative naive controls (NC, n = 8), and healthy seropositive vaccinated controls (VC, n = 32) by Luminex, spike-induced IFN-γ Elispot and an IDT. A skin biopsy 24 h after IDT and single-cell RNAseq was performed in three vaccinated volunteers.

resultsTwenty-five percent of seronegative NC had a positive Elispot (2/8) and IDT (1/4), compared to 95% (20/21) and 93% (28/30) in seropositive VC, respectively. Single-cell RNAseq data in the skin of VC showed a predominant mixed population of effector helper and cytotoxic T cells. The TCR repertoire revealed 18/1064 clonotypes with known specificities against SARS-CoV-2, among which six were spike-specific. Seronegative immunocompromised patients with positive Elispot and IDT were in 83% (5/6) treated with B cell-depleting reagents, while those with negative IDT were all transplant recipients.

conclusionsOur results indicate that delayed local reaction to IDT reflects vaccine-induced T-cell immunity opening new perspectives to monitor seronegative patients and elderly populations with waning immunity.

Indexed as

COVID-19T-LymphocytesAgedAntibodies, ViralBiomarkersCOVID-19 VaccinesHumansImmunocompromised HostmRNA VaccinesSARS-CoV-2Skin TestsVaccinationAntibodies, ViralBiomarkersCOVID-19 VaccinesmRNA VaccinesCOVIDImmunosuppressionSARS-CoV-2SkinT cellsVaccine

Identifiers

PMID37321353
PMCPMC10264165
OpenAlexW4380786235

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.